|
GB9305623D0
(en)
|
1993-03-18 |
1993-05-05 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
EP0689535B1
(en)
|
1993-03-18 |
1998-09-23 |
MERCK SHARP & DOHME LTD. |
Benzimidazole derivatives
|
|
GB9305641D0
(en)
|
1993-03-18 |
1993-05-05 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US5763263A
(en)
|
1995-11-27 |
1998-06-09 |
Dehlinger; Peter J. |
Method and apparatus for producing position addressable combinatorial libraries
|
|
US6960589B2
(en)
|
2001-03-09 |
2005-11-01 |
Abbott Laboratories |
Benzimidazoles that are useful in treating sexual dysfunction
|
|
JP4637481B2
(ja)
|
2001-10-19 |
2011-02-23 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
Ｃｄｓ１／ｃｈｋ２阻害剤および癌治療における化学療法または放射線療法の補助剤としての２−フェニルベンズイミダゾールおよびイミダゾ−［４，５］−ピリジン
|
|
US20040127504A1
(en)
|
2002-09-06 |
2004-07-01 |
Cowart Marlon D. |
Benzimidazoles that are useful in treating sexual dysfunction
|
|
CA2523743A1
(en)
|
2003-04-30 |
2004-11-18 |
The Institutes For Pharmaceutical Discovery, Llc |
Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
|
|
ATE478067T1
(de)
|
2006-03-31 |
2010-09-15 |
Janssen Pharmaceutica Nv |
Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
|
|
WO2008012623A1
(en)
|
2006-07-25 |
2008-01-31 |
Pfizer Products Inc. |
Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
|
|
SG174125A1
(en)
|
2009-04-02 |
2011-10-28 |
Merck Serono Sa |
Dihydroorotate dehydrogenase inhibitors
|
|
EP2414348B1
(en)
|
2009-04-03 |
2013-11-20 |
Merck Sharp & Dohme Corp. |
Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
|
|
CN103221404B
(zh)
|
2010-05-13 |
2015-12-16 |
安姆根有限公司 |
可用作pde10抑制剂的不饱和氮杂环化合物
|
|
HUE049152T2
(hu)
|
2012-07-01 |
2020-09-28 |
Novo Nordisk As |
Hosszantartó hatású GLP-1 peptidek alkalmazása
|
|
WO2015166398A1
(en)
|
2014-04-30 |
2015-11-05 |
Aurigene Discovery Technologies Limited |
3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors
|
|
JOP20190060A1
(ar)
|
2016-09-26 |
2019-03-26 |
Chugai Pharmaceutical Co Ltd |
مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
|
|
WO2018109607A1
(en)
|
2016-12-16 |
2018-06-21 |
Pfizer Inc. |
Glp-1 receptor agonists and uses thereof
|
|
JP7461104B2
(ja)
|
2017-11-29 |
2024-04-03 |
中外製薬株式会社 |
Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
|
|
CA3045644C
(en)
|
2018-06-13 |
2024-01-16 |
Pfizer Inc. |
Glp-1 receptor agonists and uses thereof
|
|
FI3806855T3
(fi)
|
2018-06-15 |
2023-05-04 |
Pfizer |
Glp-1 -reseptorin agonisteja ja niiden käyttöjä
|
|
TWI705820B
(zh)
|
2018-06-22 |
2020-10-01 |
美商美國禮來大藥廠 |
Gip/glp1促效劑組合物
|
|
JP7161605B2
(ja)
|
2018-08-31 |
2022-10-26 |
ファイザー・インク |
Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ
|
|
EA202191432A1
(ru)
*
|
2018-11-22 |
2021-10-14 |
Цилу Регор Терапьютикс Инк. |
Агонисты glp-1r и их применения
|
|
AU2020256647B2
(en)
|
2019-04-12 |
2025-07-31 |
Qilu Regor Therapeutics Inc. |
GLP-1R agonists and uses thereof
|
|
TWI751585B
(zh)
|
2019-06-28 |
2022-01-01 |
美商美國禮來大藥廠 |
類升糖素肽1受體促效劑
|
|
WO2021018023A1
(zh)
|
2019-08-01 |
2021-02-04 |
济南泰达领创医药技术有限公司 |
小分子glp-1受体调节剂
|
|
CR20220178A
(es)
|
2019-10-25 |
2022-06-15 |
Gilead Sciences Inc |
Compuestos moduladores de glp-1r
|
|
KR20210059584A
(ko)
|
2019-11-15 |
2021-05-25 |
일동제약(주) |
Glp-1 수용체 작용제 및 이의 용도
|
|
ES3029360T3
(en)
|
2019-11-15 |
2025-06-24 |
Ildong Pharmaceutical Co Ltd |
Glp-1 receptor agonist and use thereof
|
|
EP4069686B1
(en)
|
2019-12-02 |
2025-01-22 |
Hyundai Pharm Co., Ltd. |
Glp-1 receptor agonist
|
|
CA3163979A1
(en)
|
2019-12-10 |
2021-06-17 |
Pfizer Inc. |
Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
|
|
SI4097097T1
(sl)
|
2020-01-29 |
2025-04-30 |
Gilead Sciences, Inc. |
Spojine, ki modulirajo glp-1r
|
|
PT4097099T
(pt)
|
2020-02-07 |
2024-07-19 |
Gasherbrum Bio Inc |
Agonistas heterocíclicos de glp-1
|
|
CN115697999A
(zh)
|
2020-02-13 |
2023-02-03 |
加舒布鲁姆生物公司 |
杂环glp-1激动剂
|
|
MX2022011349A
(es)
|
2020-03-18 |
2022-11-10 |
Lg Chemical Ltd |
Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo.
|
|
MX2022010811A
(es)
|
2020-03-27 |
2022-09-27 |
Pfizer |
Tratamiento de la diabetes tipo 2 u obesidad o sobrepeso con el acido 2-[(4-{6-[(4-ciano-2-fluorobencil)oxi]piridin-2-il}piperidin -1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-bencimidazol-6-carboxil ico o una sal farmaceutica del mismo.
|
|
TW202144340A
(zh)
|
2020-04-03 |
2021-12-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
|
|
CN113493447B
(zh)
|
2020-04-03 |
2024-06-11 |
轩竹(北京)医药科技有限公司 |
Glp-1受体激动剂
|
|
WO2021219019A1
(en)
|
2020-04-29 |
2021-11-04 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
PT4157832T
(pt)
|
2020-05-27 |
2024-07-30 |
Qilu Regor Therapeutics Inc |
Formas de sal e cristal de agonistas de glp-1r e utilizações dos mesmos
|
|
CN111548311B
(zh)
|
2020-06-04 |
2021-04-23 |
山西医科大学 |
一种小分子glp-1r激动剂及其应用
|
|
PH12022553313A1
(en)
|
2020-06-04 |
2023-04-12 |
Hangzhou Sciwind Biosciences Co Ltd |
Five-membered heteroaromatic imidazole compound and use thereof
|
|
WO2021249492A1
(zh)
|
2020-06-10 |
2021-12-16 |
南京明德新药研发有限公司 |
甲基取代的苯并二噁唑类化合物及其应用
|
|
TW202214610A
(zh)
|
2020-06-19 |
2022-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
６－側氧－３，６－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
|
|
WO2021259309A1
(zh)
|
2020-06-24 |
2021-12-30 |
广州市恒诺康医药科技有限公司 |
Glp-1受体激动剂及其药物组合物和用途
|
|
KR20260040657A
(ko)
|
2020-07-20 |
2026-03-25 |
에코진 인크. |
테트라히드로피라졸로-피라지닐-디히드로이미다졸론 또는 테트라히드로피라졸로-피리디닐-디히드로이미다졸론 화합물 및 그의 사용 방법
|
|
PE20231181A1
(es)
|
2020-08-06 |
2023-08-11 |
Gasherbrum Bio Inc |
Agonistas del glp-1 heterociclicos
|
|
TW202214622A
(zh)
|
2020-08-06 |
2022-04-16 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Ｇｌｐ－１ｒ促效劑及其用途
|
|
JP2023538408A
(ja)
|
2020-08-21 |
2023-09-07 |
ターンズ・ファーマシューティカルズ・インコーポレイテッド |
Ｇｌｐ－１ｒ作動薬としての化合物
|
|
JP2023538949A
(ja)
|
2020-08-28 |
2023-09-12 |
ガシャーブラム・バイオ・インコーポレイテッド |
ヘテロ環ｇｌｐ－１アゴニスト
|
|
JP7812052B2
(ja)
|
2020-09-01 |
2026-02-09 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
縮合イミダゾール誘導体、その調製方法及びその医薬的応用
|
|
US20230322771A1
(en)
|
2020-09-07 |
2023-10-12 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
WO2022052958A1
(en)
|
2020-09-10 |
2022-03-17 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
CN115515956B
(zh)
|
2020-09-29 |
2024-06-25 |
深圳信立泰药业股份有限公司 |
一种苯并咪唑类衍生物及其制备方法和医药用途
|
|
CN116348464B
(zh)
|
2020-10-12 |
2026-06-16 |
杭州中美华东制药有限公司 |
苯并咪唑酮类glp-1受体激动剂及其用途
|
|
WO2022078380A1
(en)
|
2020-10-13 |
2022-04-21 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
JP2023546055A
(ja)
*
|
2020-10-13 |
2023-11-01 |
ガシャーブラム・バイオ・インコーポレイテッド |
ヘテロ環ｇｌｐ－１アゴニスト
|
|
US12516041B2
(en)
|
2020-10-14 |
2026-01-06 |
Qilu Regor Therapeutics Inc. |
Crystal forms of GLP-1R agonists and uses thereof
|
|
EP4247804A1
(en)
|
2020-11-20 |
2023-09-27 |
Gilead Sciences, Inc. |
Polyheterocyclic glp-1 r modulating compounds
|
|
WO2022111624A1
(zh)
|
2020-11-27 |
2022-06-02 |
深圳信立泰药业股份有限公司 |
一种苯并咪唑类衍生物及其制备方法和医药用途
|
|
CN114591308B
(zh)
|
2020-12-03 |
2024-03-08 |
苏州闻泰医药科技有限公司 |
一类glp-1r受体激动剂化合物及其用途
|
|
KR20230124956A
(ko)
|
2020-12-25 |
2023-08-28 |
스촨 하이스코 파마수티컬 씨오., 엘티디 |
5원 고리 유도체 및 이의 의학적 용도
|
|
US20240252492A1
(en)
|
2021-01-28 |
2024-08-01 |
Carmot Therapeutics ,Inc. |
Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
|
|
US12180197B2
(en)
|
2021-03-11 |
2024-12-31 |
Gilead Sciences, Inc. |
GLP-1R modulating compounds
|
|
EP4304711A1
(en)
|
2021-03-11 |
2024-01-17 |
Gilead Sciences, Inc. |
Glp-1r modulating compounds
|
|
EP4317145A4
(en)
|
2021-03-24 |
2025-03-12 |
Shionogi & Co., Ltd |
Pharmaceutical composition containing glp-1 receptor agonist having fused ring
|
|
US20220348564A1
(en)
*
|
2021-03-24 |
2022-11-03 |
Eccogene (Shanghai) Co., Ltd. |
Phenyl-[1,3]dioxolo[4,5-c]pyridinyl-phenyl-, phenyl-[1,3]dioxolo[4,5-c]pyridinyl-heteroaryl-, or phenyl-(1,3)dioxo[4,5-c]pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo[d]imidazole-carboxylic acid derivatives and methods of using same
|
|
ES2925124B2
(es)
|
2021-03-29 |
2024-04-08 |
Fundacion Univ San Antonio |
Tratamiento de la obesidad
|
|
US20240300928A1
(en)
|
2021-04-08 |
2024-09-12 |
Lg Chem, Ltd. |
Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
|
|
WO2022219495A1
(en)
|
2021-04-12 |
2022-10-20 |
Novartis Ag |
2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
|
|
LT4271672T
(lt)
|
2021-04-21 |
2026-03-10 |
Gilead Sciences, Inc. |
Karboksibenzimidazolo junginiai, moduliuojantys glp-1r
|
|
CN117177970A
(zh)
|
2021-04-30 |
2023-12-05 |
上海翰森生物医药科技有限公司 |
多环类衍生物调节剂、其制备方法和应用
|
|
CA3217720A1
(en)
|
2021-05-03 |
2022-11-10 |
Xiaohui Du |
Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
|
|
AU2022269073A1
(en)
|
2021-05-07 |
2023-11-23 |
ALX Oncology Inc. |
Exatecan derivatives and antibody-drug conjugates thereof
|
|
TWI843104B
(zh)
|
2021-05-20 |
2024-05-21 |
美商美國禮來大藥廠 |
類升糖素肽1受體促效劑
|
|
MX2023014740A
(es)
|
2021-06-10 |
2024-03-13 |
Antag Therapeutics Aps |
Tratamiento de la obesidad y trastornos relacionados con la obesidad.
|
|
CN117098758A
(zh)
|
2021-06-24 |
2023-11-21 |
杭州中美华东制药有限公司 |
Glp-1受体激动剂及其组合物和用途
|
|
US20240382471A1
(en)
|
2021-07-21 |
2024-11-21 |
Hepagene Therapeutics (HK) Limited |
Glucagon-like peptide-1 receptor modulators and uses thereof
|
|
CN113480534B
(zh)
|
2021-07-23 |
2022-05-13 |
广州必贝特医药股份有限公司 |
苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
|
|
US20240360109A1
(en)
|
2021-08-04 |
2024-10-31 |
Shanghai Hansoh Biomedical Co., Ltd. |
Cycloalkene derivative regulator, preparation method therefor, and application thereof
|
|
US20240366639A1
(en)
|
2021-08-12 |
2024-11-07 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
EP4392137A1
(en)
|
2021-08-27 |
2024-07-03 |
Versanis Bio, Inc. |
Combination therapies
|
|
KR20240053617A
(ko)
|
2021-08-30 |
2024-04-24 |
민드랭크 에이아이 리미티드 |
Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물
|
|
CN117940422A
(zh)
|
2021-08-31 |
2024-04-26 |
辉瑞大药厂 |
2-[(4-{6-[(4-氰基-2-氟芐基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸，1,3-二羟基-2-(羟甲基)丙-2-胺盐的固体形式
|
|
KR20240056719A
(ko)
|
2021-09-08 |
2024-04-30 |
시오노기 앤드 컴파니, 리미티드 |
항비만 작용이 관여하는 질환의 예방 및 치료용 의약
|
|
AU2022349687A1
(en)
|
2021-09-27 |
2024-05-16 |
Janssen Pharmaceutica Nv |
Imidazopyridazine il-17 inhibitor compounds
|
|
SI4408840T1
(sl)
|
2021-09-27 |
2025-12-31 |
Terns Pharmaceuticals, Inc. |
Benzimidazolne karboksilne kisline kot agonisti GLP-1R
|
|
WO2023057427A1
(en)
|
2021-10-05 |
2023-04-13 |
Astrazeneca Ab |
Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
|
|
WO2023057429A1
(en)
|
2021-10-05 |
2023-04-13 |
Astrazeneca Ab |
Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
|
|
US20250236627A1
(en)
|
2021-10-05 |
2025-07-24 |
Astrazeneca Ab |
Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
|
|
TWI843243B
(zh)
|
2021-10-22 |
2024-05-21 |
大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司 |
作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途
|
|
US12024507B2
(en)
*
|
2021-10-25 |
2024-07-02 |
Terns Pharmaceuticals, Inc. |
Compounds as GLP-1R agonists
|
|
JPWO2023106310A1
(enExample)
|
2021-12-07 |
2023-06-15 |
|
|
|
CN114280573B
(zh)
|
2021-12-09 |
2025-09-26 |
上海禾赛科技有限公司 |
激光雷达及其测量目标反射率的方法和系统
|
|
US20250066338A1
(en)
|
2021-12-16 |
2025-02-27 |
Astrazeneca Ab |
Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
|
|
US20250042882A1
(en)
|
2021-12-16 |
2025-02-06 |
Astrazeneca Ab |
Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
|
|
CN118434745A
(zh)
|
2021-12-29 |
2024-08-02 |
西藏海思科制药有限公司 |
一种glp-1激动剂的盐及其晶型和在医药上的应用
|
|
WO2023138684A1
(en)
|
2022-01-24 |
2023-07-27 |
Gasherbrum Bio , Inc. |
Heterocyclic glp-1 agonists
|
|
JP2025506474A
(ja)
|
2022-02-09 |
2025-03-11 |
ガシャーブラム・バイオ・インコーポレイテッド |
ヘテロ環ｇｌｐ－１アゴニスト
|
|
EP4476216A4
(en)
|
2022-02-09 |
2025-12-03 |
Gasherbrum Bio Inc |
GLP-1 HETEROCYCLIC AGONISTS
|
|
JP2025505198A
(ja)
|
2022-02-10 |
2025-02-21 |
ノバルティス アーゲー |
肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体
|
|
AU2023224854A1
(en)
|
2022-02-23 |
2024-10-03 |
Terns Pharmaceuticals, Inc. |
Compounds as glp-1r agonists
|
|
EP4490155A1
(en)
|
2022-03-09 |
2025-01-15 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
JP2025510741A
(ja)
|
2022-03-21 |
2025-04-15 |
ガシャーブラム・バイオ・インコーポレイテッド |
ヘテロ環式ｇｌｐ－１アゴニスト
|
|
US20250250269A1
(en)
|
2022-04-14 |
2025-08-07 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
CN116574092B
(zh)
|
2022-05-20 |
2024-08-20 |
成都地奥九泓制药厂 |
苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用
|
|
CN114716423A
(zh)
|
2022-05-20 |
2022-07-08 |
中国科学院上海药物研究所 |
5,6-二氢-1,2,4-三嗪类化合物及其作为glp-1受体激动剂的药学用途
|
|
CN120379988A
(zh)
|
2022-08-24 |
2025-07-25 |
广州市联瑞制药有限公司 |
苯并双环类化合物及其制备方法和应用
|
|
CN119894885A
(zh)
|
2022-08-30 |
2025-04-25 |
广州市联瑞制药有限公司 |
苯并双环类化合物及其制备方法和应用
|
|
WO2024051700A1
(zh)
|
2022-09-05 |
2024-03-14 |
德睿智药(苏州)新药研发有限公司 |
作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物
|
|
CN119907794A
(zh)
|
2022-09-22 |
2025-04-29 |
盐野义制药株式会社 |
具有glp-1受体激动剂作用的稠环化合物
|
|
US20260098031A1
(en)
|
2022-09-22 |
2026-04-09 |
Shionogi & Co., Ltd. |
Monocyclic compound having glp-1 receptor agonist activity
|
|
WO2024102625A1
(en)
|
2022-11-11 |
2024-05-16 |
Eli Lilly And Company |
Glucagon-like peptide 1 receptor agonists
|
|
CR20250178A
(es)
|
2022-11-16 |
2025-06-06 |
Lilly Co Eli |
Agonistas del receptor del péptido-1 similar al glucagón
|
|
JP2026501285A
(ja)
|
2022-12-22 |
2026-01-14 |
ガシャーブラム・バイオ・インコーポレイテッド |
ヘテロ環式ｇｌｐ－１アゴニスト
|
|
CN118344349A
(zh)
|
2023-01-13 |
2024-07-16 |
中国科学院上海药物研究所 |
用作glp-1受体激动剂的4-烷氧基苯并咪唑-6-羧酸衍生物
|
|
US20240360122A1
(en)
|
2023-03-29 |
2024-10-31 |
Terns (Suzhou) Biotechnology Co., Ltd. |
Polymorphic forms and salts of a glp-1r agonist
|
|
EP4688144A1
(en)
|
2023-03-29 |
2026-02-11 |
Terns Pharmaceuticals, Inc. |
Compounds as glp-1r agonists
|